Send to

Choose Destination
Ann Epidemiol. 2011 Nov;21(11):835-41. doi: 10.1016/j.annepidem.2011.07.007.

The metabolic syndrome and risk of prostate cancer in Italy.

Author information

Dipartimento di Epidemiologia, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.



To provide information on the role of the metabolic syndrome on prostate cancer risk.


We examined data from a multicentric Italian case-control study. Cases were 1294 patients with incident, histologically confirmed prostate cancer. Controls were 1451 men hospitalized with acute, non-neoplastic conditions. All subjects were younger than 75 years. The metabolic syndrome was defined according to selected indicators of abdominal obesity, hypercholesterolemia, hypertension, and diabetes. We computed multivariate odds ratios (OR) and 95% confidence intervals (CI) using unconditional logistic regression.


Considering separate components of the metabolic syndrome, the ORs were 0.98 (95% CI, 0.72-1.34) for diabetes, 1.14 (95% CI, 0.96-1.36) for hypertension, 1.54 (95% CI, 1.26-1.89) for hypercholesterolemia, and 1.02 (95% CI, 0.86-1.21) for abdominal obesity. The OR of prostate cancer was 1.66 (95% CI, 1.22-2.28) in men with metabolic syndrome compared with those without. We found ORs of 1.02 (95% CI, 0.83-1.26) for men with one component of the metabolic syndrome, 1.12 (95% CI, 0.89-1.42) for two, 1.65 (95% CI, 1.15-2.36) for three, and 3.99 (95% CI, 1.03-15.4) for four compared with no components.


The metabolic syndrome was associated with the risk of prostate cancer in this population.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center